The hypereosinophilic syndrome: Idiopathic or not, that is the question

Haematologica

Volumn 90, Issue 5, 2005, Pages 582-584

  Cools, Jan ^a  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PHOSPHOTRANSFERASE INHIBITOR; TRYPTASE INHIBITOR;

CHRONIC LEUKEMIA; DIFFERENTIAL DIAGNOSIS; EDITORIAL; FUSION GENE; GENETIC VARIABILITY; HUMAN; HYPEREOSINOPHILIA; HYPEREOSINOPHILIC SYNDROME; IDIOPATHIC DISEASE; LYMPHOCYTE COUNT; MYELOPROLIFERATIVE DISORDER; POINT MUTATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTINEOPLASTIC AGENTS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 4; CHRONIC DISEASE; CLONE CELLS; DIAGNOSIS, DIFFERENTIAL; DRUG RESISTANCE, NEOPLASM; HUMANS; HYPEREOSINOPHILIC SYNDROME; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHOPROLIFERATIVE DISORDERS; MRNA CLEAVAGE AND POLYADENYLATION FACTORS; MYELOPROLIFERATIVE DISORDERS; ONCOGENE PROTEINS, FUSION; PIPERAZINES; POINT MUTATION; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; STAUROSPORINE; T-LYMPHOCYTE SUBSETS;

EID: 20344367076     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (18)

1. Roufosse F, Cogan E, Goldman M. Recent advances in pathogenesis and management of hypereosinophilic syndromes. Allergy 2004;59:673-89.
2. Gotlib J, Cools J, Malone JM JM 3rd, Schrier SL, Gilliland DG, Coutre SE. The FIP1L1-PDGFRα fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood 2004;103:2879-91.
3. Bain BJ. Relationship between idiopathic hypereosinophilic syndrome, eosinophilic leukemia, and systemic mastocytosis. Am J Hematol 2004;77:82-5.
4. Reiter A, Walz C, Watmore A, Schoch C, Blau I, Schlegelberger B, et al. The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. Cancer Res 2005;65:2662-7.
5. Apperley JF, Gardembas M, Melo JV, Russell-Jones R, Bain BJ, Baxter EJ, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor β. N Engl J Med 2002;347:481-7.
6. Klion AD, Noel P, Akin C, Law MA, Gilliland DG, Cools J, et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 2003; 101: 4660-6.
7. Vandenberghe P, Wlodarska I, Michaux L, Zachee P, Boogaerts M, Vanstraelen D, et al. Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias. Leukemia 2004;18:734-42.
8. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348:1201-14.
9. von Bubnoff N, Sandherr M, Schlimok G, Andreesen R, Peschle C, Duyster J. Myeloid blast crisis evolving during imatinib treatment of an FIF1L1-PDGFR a-positive chronic myeloproliferative disease with prominent eosinophilia. Leukemia 2005;19:286-7.
10. Cools J, Stover EH, Boulton CL, Gotlib J, Legare RD, Amaral SM, et al. PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRa-induced myeloproliferative disease. Cancer Cell 2003;3:459-69.
11. Cools J, Quentmeier H, Huntly BJ, Marynen P, Griffin JD, Drexler HG, et al. The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood 2004;103:2802-5.
12. Roche-Lestienne C, Lepers S, Soenen-Comu V, et al. Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics. Leukemia 2005;[Epub ahead of print].
13. La Starza R, Specchia G, Cuneo A, Beacci D, Nozzoli C, Luciano L, et al. The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1/PDGFRA but not genomic rearrangements of other tyrosine kinases. Haematologica 2005;90:596-601.
14. Malcovati L, La Starza R, Merante S, Pietra D, Mecucci C, Cazzola M. Hypereosinophilic syndrome and cyclic oscillations in blood cell counts. A clonal disorder of hematopoiesis originating in a pluripotent stem cell. Haematologica 2004; 89: 497-9.
15. Roumier AS, Grardel N, Lai JL, Becqueriaux I, Ghomari K, de Lavareille A, et al. Hypereosinophilia with abnormal T cells, trisomy 7 and elevated TARC serum level. Haematologica 2003;88:ECR24.
16. Graux C, Cools J, Melotte C, Quentmeier H, Ferrando A, Levine R, et al. Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nat Genet 2004;36:1084-9.
17. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Cancer Genome Project. Lancet 2005;365:1054-61.
18. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387-97.